The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Is The Opdivo (nivolumab) Market’s Market Value Anticipated To Evolve From 2026 To 2030?
The opdivo (nivolumab) market has seen significant expansion in recent years. It will grow from $8.34 million in 2025 to $9.01 million in 2026 at a compound annual growth rate (CAGR) of 8.1%. This historical increase is due to elements such as the approval of PD-1 inhibitors, a rising global incidence of cancer, the drawbacks of chemotherapy, positive clinical trial outcomes, and oncologists increasingly adopting immunotherapy.
The market for Opdivo (nivolumab) is projected to experience substantial expansion over the upcoming years. This market is expected to reach $12.13 million by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. This anticipated growth during the forecast period is primarily driven by factors such as the expansion into novel oncology applications, the proliferation of combination therapy approaches, improved patient selection based on biomarkers, an increase in cancer diagnoses, and elevated spending on oncology healthcare. Key developments expected during this period involve the wider application of immune checkpoint inhibitors, the growing acceptance of combined immunotherapy treatments, an increase in cancer therapies utilizing PD-1, broader deployment across various cancer types, and an emphasis on achieving improved long-term survival outcomes.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19914&type=smp
What Major Growth Factors Are Impacting The Opdivo (nivolumab) Market?
The opdivo (nivolumab) market is projected to expand propelled by the rising prevalence of non-small cell lung cancer (NSCLC). This form of lung cancer accounts for roughly 85% of all lung cancer cases, with its growing incidence primarily stemming from factors such as smoking, exposure to environmental pollutants, genetic mutations, and a family history of cancer. Opdivo functions by inhibiting the PD-1 receptor on immune cells, thereby enhancing the body’s immune response to identify and attack cancer cells. For instance, in 2024, the American Cancer Society, a US-based health organization, reported 234,580 new cases of lung cancer diagnosed in the US, with 80% being NSCLC, indicating an increase compared to 2023, when 238,340 people were diagnosed with lung cancer. Consequently, the increasing incidence of non-small cell lung cancer is a key driver for the growth of the opdivo (nivolumab) market.
How Is The Opdivo (nivolumab) Market Structured Across Different Market Segments?
The opdivo (nivolumab) market covered in this report is segmented –
1) By Type: 40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL
2) By Dosage: Injection, Solution, Other Dosages
3) By Application: Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications
4) By End-User: Hospitals, Clinics, Other End Users
What Trends Are Affecting The Opdivo (nivolumab) Market Dynamics?
Major companies operating in the Opdivo (nivolumab) market are prioritizing the development of advanced combination therapies. These efforts aim to enhance treatment efficacy, overcome resistance mechanisms, and expand applications across multiple cancer types. Combination therapy involves the strategic deployment of Opdivo (nivolumab) alongside other agents, such as chemotherapy, to provide a more comprehensive treatment approach for advanced cancer patients. An illustration of this is the Food and Drug Administration, a US-based federal agency, approving Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment in October 2024. This is to be followed by single-agent nivolumab as adjuvant therapy after surgery, for adults with resectable non-small cell lung cancer who do not have known EGFR or ALK mutations. This approval allows Opdivo to be utilized both before and after surgery, thereby improving therapeutic outcomes for eligible patients.
Who Are The Prominent Players Across The Opdivo (nivolumab) Market?
Major companies operating in the opdivo (nivolumab) market are Bristol-Myers Squibb, Ono Pharmaceutical
Access The Complete Opdivo (nivolumab) Market Report:
https://www.thebusinessresearchcompany.com/report/opdivo-nivolumab-global-market-report-
Which Region Leads The Opdivo (nivolumab) Market By Size?
North America was the largest region in the 0pdivo (nivolumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opdivo (nivolumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model